166 filings
Page 3 of 9
8-K
fph9hkb2e61hkl3vi6
10 Nov 22
T2 Biosystems Announces Third Quarter 2022 Financial Results
5:01pm
8-K
brdmm2
7 Nov 22
Departure of Directors or Certain Officers
9:00am
8-K
abswgt1x8oo655ehs3j
14 Oct 22
T2 Biosystems Highlights Multiple New Studies Demonstrating Improved Rapid Detection Across Several Patient Populations
9:00am
8-K
lkmf5s w4y61sbr1wf1
13 Oct 22
T2 Biosystems Announces Plan to Commercialize a Diagnostic Test for Early Lyme Disease
9:00am
8-K
acostu30v
12 Oct 22
Material Modifications to Rights of Security Holders
4:01pm
8-K
xc0qoj 2ee
12 Oct 22
T2 Biosystems Announces Preliminary Third Quarter 2022 Financial Results and Updates 2022 Financial Outlook
8:47am
8-K
tgv 90h1lobd
30 Sep 22
Entry into a Material Definitive Agreement
4:06pm
8-K
gbvpiwvmaw2agjdm924f
30 Sep 22
Entry into a Material Definitive Agreement
4:00pm
8-K
1z831beycf2s8f0z9f
30 Aug 22
Other Events
9:00am
8-K
qpaefedh c78qen
17 Aug 22
T2 Biosystems Announces Second Quarter 2022 Financial Results
4:00pm
8-K
9wzmxxe
9 Aug 22
T2 Biosystems to Explore Potential to Develop Rapid Molecular Diagnostic Test for Philip Trip Taylor, Gilmartin Group
8:31am
8-K
2hz7nlg348l4l xag6n
25 Jul 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
10:00am
8-K
liqjkkdypw2krx
11 Jul 22
T2 Biosystems Receives FDA Breakthrough Device Designation for the T2Lyme Panel
8:30am
8-K
vqbkitozbm
6 Jul 22
T2 Biosystems Announces Preliminary Second Quarter 2022 Financial Results
8:43am
8-K
32mdwjb71 0nrml30r
10 Jun 22
Other Events
8:50am
8-K
ihw0j3n
24 May 22
Other Events
5:01pm
8-K
q118o1jnzdmxw
11 May 22
T2 Biosystems Announces First Quarter 2022 Financial Results
4:25pm
8-K
mk84y2 df5ecgu
27 Apr 22
T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for T2Biothreat Panel
8:30am
8-K
owhk90sx ubvp
12 Apr 22
Regulation FD Disclosure
4:01pm
8-K/A
rhy g1ziy28
1 Apr 22
Entry into a Material Definitive Agreement
4:01pm